ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise
Patients Progressing On PD-1/PD-L1s Need Options
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
You may also be interested in...
Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.
Timing means full EU approval could coincide with US FDA authorization later this year.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.